Exact Mass: 259.0957
Exact Mass Matches: 259.0957
Found 23 metabolites which its exact mass value is equals to given mass value 259.0957,
within given mass tolerance error 0.0002 dalton. Try search metabolite list with more accurate mass tolerance error
4.0E-5 dalton.
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
BEMORADAN
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
Caerulomycin I
A pyridine alkaloid that is 2,2-bipyridine-6-carboxamide substituted by methoxy groups at position 4 and carbamoyl nitrogen respectively. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity.
(6E)-3,4-dimethoxy-6-(nitrosomethylidene)-2-pyridin-2-yl-1H-pyridine
Lenalidomide
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-(2-HYDROXY-PHENYL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXYLIC ACID
ciclobendazole
P - Antiparasitic products, insecticides and repellents > P02 - Anthelmintics > P02C - Antinematodal agents > P02CA - Benzimidazole derivatives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
1-[4-(4-METHYL-4H-PYRAZIN-1-YL)-3-NITRO-PHENYL]-ETHANONE
methyl 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)acetate
Methyl 2-amino-4-(3-methoxyphenyl)pyrimidine-5-carboxylate
ethyl 8-cyano-7-Methoxy-2-MethyliMidazo[1,2-a]pyridine-3-carboxylate
(3R)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
caerulomycin C
A pyridine alkaloid that is 2,2-bipyridine substituted by methoxy groups at positions 3 and 4 and a (E)-(hydroxyimino)methyl group at position 6. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity.
